Summary: This week we delve into the world of fetal cardiology to review a recent report on fetal SVT. Are there factors in fetal life that would predict postnatal SVT? How should transesophageal pacing factor into decisions in postnatal life? How does the team at Lurie Children’s choose a 2nd agent for fetal SVT when digoxin is ineffective? Are there differences in the clinical presentation of infants prenatally diagnosed with SVT versus those diagnosed after fetal life? We speak with former EP fellow at Lurie Children's Hospital, Dr. Thomas Carberry, who is presently a pediatric electrophysiologist at DeVos Children’s Hospital. <a href="https://doi.org/10.1016/j.jacep.2022.06.003" rel="noopener">https://doi.org/10.1016/j.jacep.2022.06.003</a>
